Clik here to view.
Cipher posts Q&A about Paragraph IV Certification
Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND), in response to questions from shareholders about a Paragraph IV Certification received by its U.S. marketing partner, Ranbaxy Laboratories, has posted on...
View ArticleClik here to view.
Cipher Pharma chairman to retire
William Garriock, chairman of Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND), is retiring from active business and has resigned as chairman, effective tomorrow. “On behalf of the board, i would like to...
View ArticleClik here to view.
Cipher gets Absorica milestone payment
Cipher Pharmaceuticals’ (OTCBB:CPHMF; TSX:DND) marketing partner for Absorica has reached a cumulative sales milestone in accordance with the parties’ commercial agreement, triggering a one-time...
View ArticleClik here to view.
Cipher names Gerald McDole as chairman
Gerald McDole Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) has appointed Gerald McDole as chairman, effective immediately, replacing William Garriock, who resigned on Dec. 31, 2013. Mr. McDole has...
View ArticleClik here to view.
Cipher posts record Q4 and full-year 2013 results
Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) has reported fourth quarter profit of $17-million or 69 cents a share, compared with $1.5-million or 6 cents in the 2012 quarter. Revenue rose to...
View ArticleClik here to view.
Cipher partner launches Absorica in U.S.
Cipher Pharmaceuticals (TSX:DND; OTCBB:CPHMF) announced that its partner, Ranbaxy Laboratories, has begun the sales and promotion of Absorica, Cipher’s novel, patented, brand formulation of the acne...
View ArticleClik here to view.
Cipher posts record first quarter results
First quarter net income for Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) was $1.5-million or 6 cents a share on revenue of $3.3-million, compared with a profit of $125,000 or 1 cent on revenue of...
View ArticleClik here to view.
Byron Capital ups Cipher price target
Byron Capital Markets has raised its price target on “buy-rated” Cipher Pharmaceuticals (TSX:DND; OTCBB:CPHMF) to $6.25 from $5.25, after the company posted record results for the first quarter. The...
View ArticleClik here to view.
Cipher posts big jump in Q2 revenue and profits
Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) has reported net income of $3.1-million or 13 cents a share on revenue of $5.5-million for the second quarter, compared with $200,000 or 1 cent on revenue...
View ArticleClik here to view.
Cipher added to S&P/TSX SmallCap Index
As a result of its annual review, S&P Dow Jones Canadian Index Services is making changes to the S&P/TSX SmallCap Index at the close of trading this Friday, with Cipher Pharmaceuticals...
View Article